The Adelaide, Australia-based company's generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.
The company’s generic treatment for HIV in combination with other antiretroviral agents will be entitled to 180 days of market exclusivity, West-Ward said.